Normocapnia during nIPPV in chronic hypercapnic COPD reduces subsequent spontaneous PaCO2  by WINDISCH, W. et al.
Vol.96 (2002) 572^579Normocapnia during nIPPV in chronic hypercapnic
COPDreduces subsequent spontaneous PaCO2
W.WINDISCH,M.VOGEL, S. SORICHTER, E.HENNINGS,H.BREMER,H.HAMM,H.MATTHYS
AND J.C.VIRCHOW JR
Department of Pneumology,University Hospital Freiburg,Germany
Abstract Hypercapnia has been accepted during nasal intermittent positive pressure ventilation (nIPPV) and during
subsequent spontaneous breathing in patients with chronic hypercapnic respiratory failure (HRF) due to COPD.We
testedthehypothesis thatnIPPVaimedatnormalizing PaCO2willreduce PaCO2 during subsequent spontaneousbreath-
ing.For that purpose14 consecutive inpatients (age 61.4+9.9 years) with chronic HRF due to COPDwere established on
passive pressure-controlled nIPPV in a stepwise approach. Assisted ventilationwith supplemental oxygen to reach nor-
moxemiawas started followedbypassiveventilationwith a stepwiseincrementintheinspiratorypressure and finallybya
stepwise increase inthe respiratoryrate to establishnormocapnia.Baseline pulmonary functionparameterswere:FEV1
0.97+0.43 l, PaCO2 59.5+8.4mmHg, PaO2 49.9+7.8mmHg,HCO3
 35.6+5.2mmol/l, pH 7.39+0.04.Normoxemia as
well as normocapnia was thus established by decreasing PaCO2 by19.5+7.0mmHg during nIPPV within 8.8+3.8 days
(Po0.001) (inspiratory pressure 29.8+3.8mmHg, respiratory rate 22.9+1.9 BPM). Spontaneous PaCO2 measured 4 h
aftercessationofnIPPVdecreasedto 46.0+5.5mmHg (Po0.001), andHCO3decreasedto 27.2+3.0mmol/l (Po0.001).
At 6 months of follow-up,11patients continued nIPPV with stable blood gases and with a decrease of P0.1/Plmax from
9.4+4.3% to 5.9+2.0% (Po0.005). In conclusion, normalization of PaCO2 by passive nIPPV in patients with HRF due to
COPD is possible and leads to a significant reduction of PaCO2 during subsequent spontaneous breathing and is asso-
ciatedwith improvedparameters of respiratorymuscle function.r2002 Publishedby Elsevier Science Ltd
doi:10.1053/rmed.2002.1326, available online athttp://www.idealibrary.comonINTRODUCTION
Inspiratorymuscle fatigue has been recognized as a main
cause of failing of the respiratory pump leading to hyper-
capnic respiratory failure (HRF) (1). Nasal intermittent
positivepressureventilation (nIPPV) is awell-established
treatment forHRFdue to chestwall deformities andneu-
romuscular diseases (2^7).This technique has also been
increasingly used in patients with HRF due to COPD
where nIPPV is usually established during stable disease
(3,5^9), but also during acute exacerbation (7,10^12) and
to assist weaning from mechanical ventilation (7, 13, 14).
Recent studies including patients with chronic HRF due
to COPD could demonstrate improvements in PaCO2
during spontaneous breathing following nIPPV (5,9,15,16).
The mechanisms underlying this e¡ect are incompletely
understood, but improvements in respiratory muscleAccepted 5 February 2002.
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following appropriate unloading and resting respiratory
muscles has been shown to result in a decrease of
spontaneous PaCO2 (7,17^19). In addition, an improved
respiratory system compliance by reversingmicroatelec-
tasis of the lung and resetting of the CO2-threshold have
been postulated as important factors in improving spon-
taneous PaCO2 independently of respiratory muscle re-
lief (7,15).
In practice, mild-to-moderate hypercapnia has been
generally accepted during nIPPVas well as during subse-
quent spontaneous breathing in patients with COPDde-
spite the fact that an increased inspiratory load and a
decreased inspiratory muscle strength were correlated
with an elevated PaCO2 (20,21). Yet, patients with nor-
mocapnic COPD have been shown to have a higher ven-
tilatory reserve than patients with hypercapnic COPD
(20). In another study, 72.8% of patients who could not
be weaned from invasive ventilation using assisted venti-
lation modes for470 days could be weaned within 8.9
days by passive ventilation aiming at normocapnia, and
this was followed by periods of spontaneous breathing
with an increase of inspiratory muscle strength (22).
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capnia might lead to a more signi¢cant improvement in
respiratory function than assisted ventilation. In a recent
study, a signi¢cant decrease in PaCO2 during subsequent
spontaneous breathing within the ¢rst 2 years after
initiation of nIPPV was associated with long-term survi-
val in patients with COPD suggesting that a maximal
reduction of PaCO2 during ventilation and spontaneous
breathing might be clinically important (3). In addition,
it was concluded in another study that the attempt to
normalize arterial blood gasmeasurements (ABG) in hy-
percapnic COPD contributed to an improved outcome
in these patients (23). Therefore, it has been suggested
to adjust ventilator settings to achieve normalization
of ABG with the best comfort to the patient (4,24).
However, while most patients with HRF due to restric-
tive ventilatory disorders can be ventilated towards
normocapnia, most patients with COPD remain hyper-
capnic even during ventilation (3,5,25). Therefore,
the aim of the present study was to test the hypothesis
that passive nIPPV using higher inspiratory pressures
than previously reported in the literature can normalize
hypercapnia in patients with chronic HRF due to
COPD during ventilation assuming that this might
improve the PaCO2-threshold as indirectly measured by
a reduction in PaCO2 during subsequent spontaneous
breathing.
PATIENTSANDMETHODS
Patients
Fourteen consecutive patients (¢ve female, nine male),
mean age 61.4+9.9 (range 49^80) years, with COPD
and chronic HRF were enrolled. All had been heavy
smokers (43.4+13.7 packyears). Half of them were
transferred from another clinic for evaluation of treat-
ment with nIPPV.Half of themwere seen as outpatients
in our clinic. All patients were clinically stable with no
evidence of an acute exacerbation. Three patients
with minor hypercapnia (PaCO2o55mmHg for at least
3 months) had been established on long-term oxygen
therapy (LTOT) prior to enrollment (case four, nine
and twelve), but patients’ symptoms worsened in terms
of dyspnea on exertion and fatigue while PaCO2 in-
creased during LTOT. Eleven patients presenting
with the typical symptoms of HRF such as fatigue,
dyspnea and morning headache and with major hyper-
capnia (PaCO2455mmHg for at least 3months (except
case 2)) had no LTOT prior to enrollment. None of the
patients had any type of ventilatory support prior to en-
rollment. All patients were on antiobstructive medica-
tions (oral theophylline, inhaled formoterol and
budesonide) prior to enrollment. These medications
were not changed throughout the study and subsequent
follow-up.Ventilators
A pressure-controlled ventilator (PV401, Breass, Swe-
den) was used. Inspiration times can be set between 0.5
and 5 s. A pressure-controlled trigger can be chosen be-
tween2 and+8mbar. Inspiratorypressuresrange from
6 to 40mbar, and the respiratory rate can be set be-
tween 6 and 40 breaths per minute (BPM). The time in
which the maximal pressure is reached can be adjusted
at an arbitrary scale between 1 and 9, where higher va-
lues indicate less time needed to reach maximal pres-
sure.Higher values between 8 and 9 were chosen in our
study.
Study design
Prior to the study pulmonary function (Masterlab, Jae-
ger,Wuerzburg,Germany) and inspiratory mouth pres-
sures (ZANs, Oberthulba, Germany) were measured.
Initial ABG were sampled from the radial artery (AVL
Compact 2 Blood Gas Analyzer, Roswell, GA, U.S.A.)
while patients were breathing room air at rest. Patients
were started on nIPPV using a conventional nasal mask
(Respironicss, Pittsburgh, PA,U.S.A.). After a period of
acclimatization, patients were instructed to use the ven-
tilator during the whole night and during daytime for up
to 6h (14h/day) until normocapnia was achieved. From
then on the ventilator was used during bedtime and for
up to 2h during midday (10h/day). Patients with nasal ir-
ritations ormask leaks received an individual nasalmask.
The ventilator settings were adjusted individually as de-
scribed below to normalize ABG maintaining the best
comfort for the patient.
The ventilator was used during the initiation of nIPPV
with inspiratory pressures between12 and18mbar and a
low trigger threshold (0.5 to 0.1mbar). Oxygen sa-
turation was measured continuously by pulse oxymetry.
Supplemental oxygen was added to maintain SaO2
495%. Subsequently, the inspiratory pressure was in-
creased stepwise until a further increase was not toler-
ated by the patient. Next, the respiratory rate was
increased beyond the spontaneous rate to establish pas-
sive ventilation. Further increases in respiratory rate
were aimed at a progressive decrease of PaCO2 towards
normocapnia. In some cases, the inspiratory pressure
had to be decreased slightly to allow a further increase
in the respiratory rate while maintaining an l:E ratio of
approximately1:2.
ABG drawn from the radial artery were measured
daily once in the early morning while on nIPPV (for at
least 4 h during night). Settings were increased when
ABG during nIPPV still revealed hypercapnia. Further
ABG during nIPPV were drawn later in the day in order
to verify the adjustment of the ventilator. In addition,
ABGwere drawn during spontaneous breathing at least
4 h after cessation of ventilation on days when normo-
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discharged when normocapnia (PaCO2 37^43mmHg)
during nIPPV had been achieved or PaCO2 did not show
a further decrease during nIPPV for aminimumof 3 days.
A follow-up was carried out at 6 weeks and 6 months
after initiation of nIPPV with measurements of ABG,
mouth occlusion pressures, and pulmonary function
testing together with a detailed non-standardized his-
tory in order to investigate long-term e¡ects of nIPPV
aimed at achieving normocapnia.
Statistical analysis
Statistical analysis was performedusing Sigma-Stat (Ver-
sion 2.03, SPSS Inc., Chicago, IL, U.S.A.). Data are pre-
sented as mean+standard deviation after testing for
normal distribution. Statistical analysis of all data was
performed with the paired t-test, one-way ANOVA for
repeatedmeasurements with pairwisemultiple compar-
ison using the Student^Newman^Keuls method and
with the Pearson product moment correlation. Statisti-
cal signi¢cancewas assumedwith a P-value ofo0.05.
RESULTS
All patients enrolled were hypoxemic and hypercapnic,
and had signs and symptoms of COPD for 43 months
(Table1).Bodymass index was 28.4+7.2kg/m2. Pulmon-
ary function testing revealed a severe air£ow obstruc-
tion with an FEV1of 0.97+0.43 l and an FEV1/VC-ratio of
45+9.7%. PaCO2 was correlated to FEV1 (r=0.57,
Po0.05) and to HCO3 (r=0.76, Po0.005). InspiratoryTABLE 1. Lung functionparameters and ABG prior to initiation
Case FEV1 VC FEV1/VC TLC RV
no. (l) (l) (%) (l)
1 1.00 3.1 32 7.1
2 1.60 3.5 47 8.0
3 1.40 3.0 48 6.7
4 0.92 1.9 49 5.9
5 0.87 1.5 58 4.4
6 0.96 2.5 39 8.5
7 0.68 1.5 44 7.0
8 0.64 2.2 30 8.4
9 0.43 1.2 36 5.9
10 1.20 2.5 50 6.1
11 0.93 2.4 39 5.6
12 1.90 3.1 61 6.1
13 0.57 1.0 56 7.0
14 0.53 1.5 36 6.7
Mean 0.97 2.2 45 6.7
SD 0.43 0.8 9.7 1.1mouth pressures with a P0.1 of 0.48+0.25kPa and a
Plmax of 4.6+1.7 kPa (P0.1/Plmax 10.9+5.4%) indicated
an increased inspiratory load and decreased inspiratory
muscle strength (20,21,26). P0.1/Plmax was correlated to
FEV1 (r=0.77,Po0.005) and to IVC (r=0.81,Po0.005).
All patients were established on nIPPV using a nasal
mask.Ventilation parameters are given inTable 2. In all
patients, the respiratory rate could be increased indu-
cing totally passive ventilation. Five patients did not tol-
erate the Respironicss mask because of major leakage,
one patient additionally su¡ered from soreness on the
bridge of the nose and subsequently developed a local ul-
cer. All were successfully switched to an individually
adapted nosemask. In two patients, symptoms of gastric
distension were successfully treated by individual posi-
tioning during ventilation, a mild reduction in inspiratory
pressures and oral dimeticon t.i.d. 80mg.
PaCO2 values decreased progressively to a mean
PaCO2 of 40.0+4.6mmHg (Po0.001) following initiation
of nIPPV, corresponding to an average drop in PaCO2 of
19.5+7.0mmHg (Fig.1).This was re£ected by an increase
in pH from 7.39+0.04 to 7.45+0.04 (Po0.001).HCO3 le-
vels decreased from 35.6+5.2 to 28.5+2.1mmol/l
(Po0.001). Since oxygenwas supplementedduring nIPPV,
mean PaO2 increased from 49.9+7.8 to 75.0+9.3mmHg
(Po0.001). In all patients, themean supplemental oxygen
£owratewas1.5+1.0 l/min at the time of optimal ventila-
tion, whereas three patients did not require further ad-
ditional treatment with oxygen once PaCO2 had
returned to normal.
The mean PaCO2 after 4h following cessation of
nIPPV during subsequent spontaneous breathing was
46.0+5.5mmHg (range 36^58mmHg) with an increaseof nIPPV
/TLC PaCO2 PaO2 HCO3
 pH
(%) (mmHg) (mmHg) mmol/l
0.56 67 56 44 7.43
0.56 50 49 32 7.45
0.55 58 56 37 7.42
0.68 51 54 28 7.37
0.66 60 45 35 7.42
0.71 57 60 41 7.45
0.79 64 44 36 7.34
0.74 70 39 39 7.34
0.80 50 53 32 7.40
0.59 57 47 34 7.34
0.57 55 57 30 7.38
0.49 49 58 29 7.38
0.86 74 48 37 7.35
0.78 71 33 44 7.35
0.67 59.5 49.9 35.6 7.39
0.12 8.4 7.8 5.2 0.04
TABLE 2. Ventilationparameters and ABGduringnIPPV + supplemental oxygen
Case Pressure Frequency Insp.Time Suppl.O2 PaCO2 PaO2 HCO3
 pH
no. (mbar) (l/min) (sec) (l/min) (mmHg) (mmHg) (mmol/l)
1 30 22 0.9 1 36 78 29 7.51
2 32 21 0.9 2 36 78 26 7.50
3 25 22 0.8 0 39 67 28 7.47
4 24 22 1.0 0 38 84 29 7.45
5 30 20 0.9 2 48 63 32 7.37
6 28 23 0.8 0 34 68 29 7.45
7 28 26 0.7 3 40 70 30 7.48
8 36 25 0.7 1.5 47 85 28 7.43
9 24 26 0.8 1 39 72 26 7.43
10 28 23 0.9 2 37 64 26 7.43
11 33 21 0.9 2 36 90 28 7.48
12 34 21 0.8 2 40 65 28 7.45
13 32 24 0.9 2 43 78 27 7.43
14 33 24 1.0 3 47 88 33 7.39
Mean 29.8 22.9 0.9 1.5 40.0 75.0 28.5 7.45
SD 3.8 1.9 0.1 1.0 4.6 9.3 2.1 0.04
FIG. 1. Normalization of PaO2 and PaCO2 during nIPPV with
supplemental oxygen (n= 14).
FIG. 2. Correlation (Pearson) between PaCO2 during nIPPV
and PaCO2 during subsequent spontaneous breathing four
hours after cessation of nIPPV (n=14).
NORMOCAPNIADURINGNIPPVINHYPERCAPNICCOPD 575of 6.0+3.5mmHg compared to PaCO2 during nIPPV
(Po0.001). The corresponding PaO2 was
55.9+8.2mmHg (range 45^71mmHg) with a decrease
of 19.1+12.7mmHg compared to the PaO2 during nIPPV
with supplemental oxygen (Po0.001), the corresponding
pH was 7.43+0.05 (range 7.34^7.51) with a decrease of
0.02+0.06 compared to the pH during nIPPV (not signif-
icant) and the corresponding HCO3
 was
27.2+3.0mmol/l (range 22^34mmol/l) with a decrease
of 1.3+1.6mmol/l compared to HCO3
 during nIPPV
(Po0.05).
Compared to ABG prior to initiation of nIPPV the
PaCO2 decreased by 13.5+9.3mmHg (Po0.001), thePaO2 increased by 5.9+6.1mmHg (Po0.005), the pH in-
creasedby 0.04+0.05 (Po0.01), andHCO3 decreasedby
8.4+5.1mmol/l (Po0.001) when patients breathed room
air after 4h following cessation of nIPPV. There was a
close correlation between the PaCO2 during nIPPV and
the PaCO2 during subsequent spontaneous breathing
after initiation of nIPPV (r=0.77;Po0.005) (Fig. 2).
The mean number of days of nIPPV to reach normo-
capnia was 8.8+3.8. There was a close correlation be-
tween the number of days on nIPPV to reach
normocapnia and the following parameters: VC:
r=0.74, Po0.005; FEV1: r=0.73, Po0.005 (Fig. 3);
FIG. 3. Correlation (Pearson) between lung function para-
meters (FEV1,VC) and thenumberofdays to achieve normocap-
nia bynIPPV (n=14).
FIG. 4. PaCO2, PaO2, HCO3
 and pH (mean+SEM) during
spontaneous breathing of ambient air following nIPPV (n= 11)
(*Po0.001, }Po0.005, and &n.s. compared to values before
nIPPV).
576 RESPIRATORYMEDICINEP0.1/Plmax: r=0.70, Po0.05; PaCO2 prior to nIPPV:
r=0.59, Po0.05.
The mean hospital stay was 14.1+5.1 days which was
correlated to the number of days on nIPPV required to
reach normocapnia (r=0.80; Po0.001). The mean time
spent on the ventilator after reaching normocapnia was
9.8+2.4h/day, most of which was during night. Each pa-
tient was discharged from hospital in a clinically stable
condition and with a subjective improvement in symp-
toms with the exception of one patient (case ¢ve) who
was unable to tolerate nIPPVat night.Hewas discharged
without nIPPV and died 6 months later due to progres-
sive respiratory failure. The other patients reported a
good quality of sleep and were maintained on nIPPV at
home.
Within the following 6months, two additionalpatients
discontinued nIPPV. One patient (case nine) remained
normocapnic without further ventilation after initial
treatment, although prior to inclusion this patient had
no evidence of an acute respiratory failure. HoweverTABLE 3. Mouthocclusionpressures andlung functionparame
(n= 11)
nIPPVonset
P0.1 (kPa) 0.46+0.26
Plmax (kPa) 4.9+1.6
P0.1/Plmax (%) 9.4+4.3
FEV1 (l) 1.06+0.43
VC (l) 2.4+0.7
FEV1/VC (%) 44+9.9
TLC (l) 6.9+1.0
RV/TLC (%) 0.64+0.11
*Po0.05,**Po0.005, ***Po0.001compared to nIPPVonsether PaCO2 was only 50mmHg when she was entered
into the study.One patient (case seven) died not due to
respiratory conditions (sudden cardiac death). In the re-
maining11patientsABGremained stable for 6weeks and
6 months after initiation of nIPPV. The PaCO2 at 6
months was 38.7+2.6mmHg, the PaO2 was
78.8+14.1mmHg, pH was 7.46+0.03 and the HCO3

27.8+1.5mmol/l while on nIPPV. At this follow-up visit,
the PaCO2 after 4h of spontaneous breathing
was 43.0+1.9mmHg, the PaO2 was 59.8+10.1mmHg,
the pH was 7.44+0.02 and the HCO3
 was
28.9+1.9mmol/l (Fig. 4). The P0.1 decreased signi¢cantly
and Plmax increased not signi¢cantly as shown in
Table 3. Accordingly, this resulted in a signi¢cant
decrease of the P0.1/Plmax-ratio (Table 3). In addition,
there was no signi¢cant change in lung function
parameters and hyperin£ation (Table 3).The mean time
on nIPPVat 6months follow-upwas10.2+3.1h/day, most
of which was during night. All patients were clinicallytersinpatientswho continuednIPPVover a periodof 6months
6-weeks follow-up 6-months follow-up
0.29+0.14* 0.31+0.10*
5.4+1.5 5.5+1.4
5.2+2.5*** 5.9+2.0**
0.99+0.44 1.06+0.48
2.2+0.8 2.5+0.7
45+10.3 44+13.3
6.8+1.3 6.7+1.1
0.66+0.12 0.64+0.12
.
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admission due to respiratory events since the onset of
nIPPV. All patients reported an improvement in their
physical function andwell-being.
Discussion
Our data show that normalization of PaCO2 by nIPPV in
patientswithHRF due toCOPD is possible and leads to a
signi¢cant reduction of PaCO2 during subsequent spon-
taneousbreathing.During the initiation of nIPPVassisted
ventilation with supplemental oxygen allowed normali-
zation of PaO2 in all patients without any signi¢cant de-
terioration in hypercapnia. Subsequently, ventilation
parameters were increased stepwise until normocapnia
was reached by passive ventilation. Almost 9 days of
nIPPV were needed to achieve normocapnia. Interest-
ingly, there was a statistically signi¢cant correlation be-
tween the time needed to achieve normocapnia and
pulmonary function parameters (FEV1 and VC), PaCO2
prior to nIPPV and the P0.1/Plmax-ratio suggesting that
the time on nIPPVrequired to reach normocapnia is de-
pendent on the severity of the disease.Relatively high in-
spiratory pressures with a mean of 29.8+3.8mbar and
relatively high respiratory rates with a mean of
22.9+1.9BPM were necessary to achieve normocapnia.
This is in contrast to low-pressure ventilation with e.g.
BiPAPs ventilators (Respironics Inc., Murrysville, PA,
U.S.A., peak inspiratory pressure: 22 cmH2O) which
were insu⁄cient to normalize PaCO2 in hypercapnic
COPD. In these studies, BiPAPs in the spontaneous
mode did not change hypercapnia in patients with stable
COPD (27,28). In another study, nasal pressure support
ventilation (PSV) with BiPAPs in the spontaneousmode
increasedminute ventilation (VE) by increasing tidal vo-
lume (VT) despite a reduction in respiratory rate (25).
Although this resulted in a decrease in PaCO2 by
7mmHg, patients still remained hypercapnic during ven-
tilation.
The addition of BiPAPs to oxygen has been reported
to be superior to oxygen alone to improve daytime and
overnightbloodgas values, sleep quality and quality of life
in patients with stable hypercapnic COPD (9). However,
PaCO2 decreased only by a mean of 3.3mmHg when pa-
tients were breathing room air after BiPAPs. In contrast,
in our study there was a mean decrease in spontaneous
PaCO2 of 13.5+9.3mmHg. An increase in spontaneous
PaO2 by 5.9mmHg followingnIPPVin our study was simi-
lar to other observations (5,9). Interestingly, PaCO2 dur-
ing nIPPV and PaCO2 during spontaneous breathing
following nIPPV were well correlated suggesting that if
normalization of PaCO2 canbe achievedbynIPPV thiswill
also result in a reduction in PaCO2 during subsequent
spontaneous breathing. In contrast, patients who remain
in hypercapnia even during ventilation presumably willnot have a signi¢cant decrease in spontaneous PaCO2.
Although we did not measure CO2-threshold, it might
be, therefore, suggested that an increasedCO2-threshold
in hypercapnic COPD can be temporarily decreased by
more aggressive ventilation. A high correlation between
the change in PaCO2 following nIPPV and the increase in
ventilation following CO2-rebreathing has been reported
previously (15). From these data, it was concluded that
the CNS responds to an increase in load in order to pre-
vent fatigue and not due to overt respiratory pump fail-
ure, since the reduction of PaCO2 and the increase of
inspiratory muscle strength did not correlate well. How-
ever, PaCO2 decreased only by 7mmHg (0.9kPa) which
could explain the lack of a signi¢cant increase of inspira-
tory muscle strength. In addition, it has been suggested
that bicarbonate concentration is a signi¢cant determi-
nant in setting the sensitivity of the respiratory control
mechanism to the natural carbon dioxide stimulus,
whereas changes in hydrogen ion activity as the crucial
determinant of ventilatory response aremainly regulated
bybicarbonate concentration (29). Accordingly, the appli-
cation of acetazolamide (ACET) produced metabolic
acidosis in COPD with a decrease in bicarbonate levels,
but a decrease of PaCO2 of 45mmHg combined with
an increase in VTwas observed only in six of the 15 pa-
tients (30). Furthermore, there was no correlation be-
tween the correction of PaCO2 induced by ACET and
the ventilatory response to exogenous PaCO2 in this
study indicating that the simple renal loss of bicarbonate
which lowers the pH is presumably not the onlymechan-
ism by which normalization of ventilation with lowering
of PaCO2 occurs. Interestingly, therewas a signi¢cant de-
crease of bicarbonate and PaCO2 following nIPPV in our
series. From these data it can be suggested that normal-
ization of spontaneous PaCO2 induced by acidosis-stimu-
lated breathing will occur only if renal excretion of
bicarbonate is accompanied by improvement of the re-
spiratory muscle function. This is supported by the fact
that P0.1 decreased following nIPPV in our series indicat-
ing unloading of the respiratorymuscles, whereas P0.1 in-
creased following application of ACET (30) which would
suggest to us thatACET in contrast to nIPPVas applied in
our study increase the load on the respiratory pump.
Only one patient discontinued nIPPVdue tomajor dis-
comfort indicating that the ventilation parameters used
in our study which are considerably higher than those
previously reported in the literature are well tolerated.
In addition, no harmful e¡ects of nIPPVusing higher ven-
tilation pressures occurred, and therewas no increase of
hyperin£ation following nIPPV which could have theore-
tically led to harmful e¡ects on respiratory muscle func-
tion, barotrauma or hemodynamic changes. Althoughup
to 50% of patients su¡er from gastric distension when
using a volume-cycled ventilator (3,31), normocapnia
was achieved during nIPPV in our study with a reduced
frequencyof side-e¡ectspossiblydue to amore constant
578 RESPIRATORYMEDICINEpeak inspiratory pressure when using a pressure-con-
trolled ventilator. Pressure-controlled ventilation also
has the advantage of leak compensation but it remains
unclear to which extend this might have contributed to
the successful ventilation in our study. Patients who con-
tinuedhomeventilationhadrelief of symptoms, andnone
of thepatientswas readmitted for an acute exacerbation
of HRF and presented with normocapnia during the fol-
low-up at 6 weeks and 6 months indicating clinical bene-
¢t. This was accompanied by a signi¢cant reduction in
P0.1/Plmax at follow-up visits, although lung volumes and
hyperin£ation remained unchanged suggesting that
nIPPV and not improvement in lung volumes or a de-
crease in hyperin£ationmight be responsible for the ob-
served changes. Although we do not provide direct
proof, these ¢ndings suggest alleviation of respiratory
muscle fatigue due to nIPPV, possibly due to unloading
of the respiratorymuscles.
In conclusion, pressure-controlled ventilation can nor-
malize PaCO2 in patients with severe HRF due to COPD
using relatively high inspiratory pressures and relatively
high respiratory rates withoutmajor discomfort for the
patient. Our data suggest that attempts to normalize
PaCO2 during nIPPV can lead to a prolonged improve-
ment in PaCO2 when breathing ambient air in patients
with chronic HRF due to COPD. Although not tested in
this study, wewould speculate that this e¡ect is due to a
reduction in the CO2-threshold of these patients in-
duced by renal excretion of bicarbonate following im-
provement of respiratory muscle function. Clearly,
controlled studies are needed to assess the long-term
bene¢t of establishing normocapnia in patients with
chronic HRF due to COPD.
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